Pembrolizumab-Induced Myasthenic Crisis with HyperCKemia in a Patient with Thymoma

참고문헌 (9)

1. Postow MA, "Immune checkpoint blockade in cancer therapy", J Clin Oncol, 33, pp.1974~1982 (2015)
2. Kao JC, "Neurological complications associated with anti-programmed death 1 (PD-1) antibodies", JAMA Neurol, 74, pp.1216~1222 (2017)
3. Makarious D, "Myasthenia gravis : an emerging toxicity of immune checkpoint inhibitors", Eur J Cancer, 82, pp.128~136 (2017)
4. Cavalcante P, "Autoimmune mechanisms in myasthenia gravis", Curr Opin Neurol, 25, pp.621~629 (2012)
5. Safa H, "Immune checkpoint inhibitor related myasthenia gravis : single center experience and systematic review of the literature", J Immunother Cancer, 7, pp.319~ (2019)
6. 허소영, "Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer", Journal of Clinical Neurology, 14(1), pp.115~117 (2018), 대한신경과학회[DOI]
7. March KL, "Pembrolizumab-induced myasthenia gravis : a fatal case report", J Oncol Pharm Pract, 24, pp.146~149 (2018)
8. Gonzalez NL, "Myasthenia triggered by immune checkpoint inhibitors : new case and literature review", Neuromuscul Disord, 27, pp.266~268 (2017)
9. Takamatsu K, "Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia", Ann Clin Transl Neurol, 5, pp.1421~1427 (2018)

관련 논문AI추천